Corpea
Corpea Uses, Dosage, Side Effects, Food Interaction and all others data.
Corpea is an orally active, long-acting vasodilator, which belongs to the class of medications known as syndnones. Interestingly, it is being studied as being a preventive measure in cerebral infarction .
Corpea leads to smooth muscle relaxation in the coronary blood vessels, relieving symptoms of angina and increasing blood flow to the coronary arteries.
| Trade Name | Corpea |
| Generic | Molsidomine |
| Molsidomine Other Names | Molsidomina, Molsidomine, Molsidominum |
| Type | |
| Formula | C9H14N4O4 |
| Weight | Average: 242.235 Monoisotopic: 242.101504947 |
| Groups | Approved, Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | Spain |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Corpea is a long-acting vasodilator used to treat angina pectoris, including in association with left heart failure and acute myocardial infarction.
The indications for use of molsidomine include ischemic heart disease, angina, chronic heart failure, and pulmonary hypertension .
Corpea is also used to associated treatment for these conditions: Angina Pectoris, Chronic Stable Angina Pectoris, Unstable Angina Pectoris
How Corpea works
Corpea, a cardiovascular drug, acts in a similar fashion to organic nitrates. The SIN-1A metabolite of molsidomine has a pharmacologically active group of nitric oxide, which increases levels of cyclic GMP, and decreases intracellular calcium ions in smooth muscle cells. This leads to relaxation of smooth muscle in the blood vessels, and inhibits platelet aggregation.
Volume of Distribution
98 L
Elimination Route
Peak plasma drug concentration (tmax) occurs from 1 to 2 hours after administration.
Clearance
renal excretion is the main route of elimination of the metabolites in humans (90% to 95%) About 2% of the ingested drug is excreted unchanged in the urine.
Innovators Monograph
You find simplified version here Corpea
